Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 233


Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response.

Baeuerle PA, Ding J, Patel E, Thorausch N, Horton H, Gierut J, Scarfo I, Choudhary R, Kiner O, Krishnamurthy J, Le B, Morath A, Baldeviano GC, Quinn J, Tavares P, Wei Q, Weiler S, Maus MV, Getts D, Schamel WW, Hofmeister R.

Nat Commun. 2019 May 7;10(1):2087. doi: 10.1038/s41467-019-10097-0.


Pharmacokinetic and Pharmacodynamic Relationship of Blinatumomab in Patients with Non-Hodgkin Lymphoma.

Hijazi Y, Klinger M, Kratzer A, Wu B, Baeuerle PA, Kufer P, Wolf A, Nagorsen D, Zhu M.

Curr Clin Pharmacol. 2018;13(1):55-64. doi: 10.2174/1574884713666180518102514.


Antiviral Activity of HIV gp120-Targeting Bispecific T Cell Engager Antibody Constructs.

Brozy J, Schlaepfer E, Mueller CKS, Rochat MA, Rampini SK, Myburgh R, Raum T, Kufer P, Baeuerle PA, Muenz M, Speck RF.

J Virol. 2018 Jun 29;92(14). pii: e00491-18. doi: 10.1128/JVI.00491-18. Print 2018 Jul 15.


Bispecific T cell engager (BiTE®) antibody constructs can mediate bystander tumor cell killing.

Ross SL, Sherman M, McElroy PL, Lofgren JA, Moody G, Baeuerle PA, Coxon A, Arvedson T.

PLoS One. 2017 Aug 24;12(8):e0183390. doi: 10.1371/journal.pone.0183390. eCollection 2017.


Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL.

Nägele V, Kratzer A, Zugmaier G, Holland C, Hijazi Y, Topp MS, Gökbuget N, Baeuerle PA, Kufer P, Wolf A, Klinger M.

Exp Hematol Oncol. 2017 May 18;6:14. doi: 10.1186/s40164-017-0074-5. eCollection 2017.


Bispecific T cell engaging antibody constructs targeting a universally conserved part of the viral M2 ectodomain cure and prevent influenza A virus infection.

Pendzialek J, Roose K, Smet A, Schepens B, Kufer P, Raum T, Baeuerle PA, Muenz M, Saelens X, Fiers W.

Antiviral Res. 2017 May;141:155-164. doi: 10.1016/j.antiviral.2017.02.016. Epub 2017 Mar 1.


Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.

Aldoss I, Bargou RC, Nagorsen D, Friberg GR, Baeuerle PA, Forman SJ.

Leukemia. 2017 Apr;31(4):777-787. doi: 10.1038/leu.2016.391. Epub 2016 Dec 28. Review.


Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.

Goebeler ME, Knop S, Viardot A, Kufer P, Topp MS, Einsele H, Noppeney R, Hess G, Kallert S, Mackensen A, Rupertus K, Kanz L, Libicher M, Nagorsen D, Zugmaier G, Klinger M, Wolf A, Dorsch B, Quednau BD, Schmidt M, Scheele J, Baeuerle PA, Leo E, Bargou RC.

J Clin Oncol. 2016 Apr 1;34(10):1104-11. doi: 10.1200/JCO.2014.59.1586. Epub 2016 Feb 16.


Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110.

Deisting W, Raum T, Kufer P, Baeuerle PA, Münz M.

PLoS One. 2015 Oct 28;10(10):e0141669. doi: 10.1371/journal.pone.0141669. eCollection 2015.


CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas.

Oberst MD, Fuhrmann S, Mulgrew K, Amann M, Cheng L, Lutterbuese P, Richman L, Coats S, Baeuerle PA, Hammond SA.

MAbs. 2014;6(6):1571-84. doi: 10.4161/19420862.2014.975660.


Human therapies as a successful liaison between chemistry and biology.

Baeuerle PA, Murry JA.

Chem Biol. 2014 Sep 18;21(9):1046-54. doi: 10.1016/j.chembiol.2014.08.014. Review.


Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia.

Friedrich M, Henn A, Raum T, Bajtus M, Matthes K, Hendrich L, Wahl J, Hoffmann P, Kischel R, Kvesic M, Slootstra JW, Baeuerle PA, Kufer P, Rattel B.

Mol Cancer Ther. 2014 Jun;13(6):1549-57. doi: 10.1158/1535-7163.MCT-13-0956. Epub 2014 Mar 27.


CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.

Krupka C, Kufer P, Kischel R, Zugmaier G, Bögeholz J, Köhnke T, Lichtenegger FS, Schneider S, Metzeler KH, Fiegl M, Spiekermann K, Baeuerle PA, Hiddemann W, Riethmüller G, Subklewe M.

Blood. 2014 Jan 16;123(3):356-65. doi: 10.1182/blood-2013-08-523548. Epub 2013 Dec 3.


Targeting T cells to tumor cells using bispecific antibodies.

Frankel SR, Baeuerle PA.

Curr Opin Chem Biol. 2013 Jun;17(3):385-92. doi: 10.1016/j.cbpa.2013.03.029. Epub 2013 Apr 25. Review.


T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct.

Aigner M, Feulner J, Schaffer S, Kischel R, Kufer P, Schneider K, Henn A, Rattel B, Friedrich M, Baeuerle PA, Mackensen A, Krause SW.

Leukemia. 2013 Apr;27(5):1107-15. doi: 10.1038/leu.2012.341. Epub 2012 Nov 26.


The activity of γδ T cells against paediatric liver tumour cells and spheroids in cell culture.

Hoh A, Dewerth A, Vogt F, Wenz J, Baeuerle PA, Warmann SW, Fuchs J, Armeanu-Ebinger S.

Liver Int. 2013 Jan;33(1):127-36. doi: 10.1111/liv.12011. Epub 2012 Oct 22.


Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens.

Friedrich M, Raum T, Lutterbuese R, Voelkel M, Deegen P, Rau D, Kischel R, Hoffmann P, Brandl C, Schuhmacher J, Mueller P, Finnern R, Fuergut M, Zopf D, Slootstra JW, Baeuerle PA, Rattel B, Kufer P.

Mol Cancer Ther. 2012 Dec;11(12):2664-73. doi: 10.1158/1535-7163.MCT-12-0042. Epub 2012 Oct 5.


Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL.

Topp MS, Gökbuget N, Zugmaier G, Degenhard E, Goebeler ME, Klinger M, Neumann SA, Horst HA, Raff T, Viardot A, Stelljes M, Schaich M, Köhne-Volland R, Brüggemann M, Ottmann OG, Burmeister T, Baeuerle PA, Nagorsen D, Schmidt M, Einsele H, Riethmüller G, Kneba M, Hoelzer D, Kufer P, Bargou RC.

Blood. 2012 Dec 20;120(26):5185-7. doi: 10.1182/blood-2012-07-441030. Epub 2012 Sep 28.


Clinical experience with gene therapy and bispecific antibodies for T cell-based therapy of cancer.

Baeuerle PA, Itin C.

Curr Pharm Biotechnol. 2012 Jun;13(8):1399-408. Review.


Blinatumomab: a historical perspective.

Nagorsen D, Kufer P, Baeuerle PA, Bargou R.

Pharmacol Ther. 2012 Dec;136(3):334-42. doi: 10.1016/j.pharmthera.2012.07.013. Epub 2012 Aug 24. Review.


Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.

Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS, Gökbuget N, Neumann S, Goebeler M, Viardot A, Stelljes M, Brüggemann M, Hoelzer D, Degenhard E, Nagorsen D, Baeuerle PA, Wolf A, Kufer P.

Blood. 2012 Jun 28;119(26):6226-33. doi: 10.1182/blood-2012-01-400515. Epub 2012 May 16.


The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEA.

Peng L, Oberst MD, Huang J, Brohawn P, Morehouse C, Lekstrom K, Baeuerle PA, Wu H, Yao Y, Coats SR, Dall'Acqua W, Damschroder M, Hammond SA.

PLoS One. 2012;7(5):e36412. doi: 10.1371/journal.pone.0036412. Epub 2012 May 4.


Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer.

Schmidt M, Rüttinger D, Sebastian M, Hanusch CA, Marschner N, Baeuerle PA, Wolf A, Göppel G, Oruzio D, Schlimok G, Steger GG, Wolf C, Eiermann W, Lang A, Schuler M.

Ann Oncol. 2012 Sep;23(9):2306-13. doi: 10.1093/annonc/mdr625. Epub 2012 Feb 21.


EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells.

Cioffi M, Dorado J, Baeuerle PA, Heeschen C.

Clin Cancer Res. 2012 Jan 15;18(2):465-74. doi: 10.1158/1078-0432.CCR-11-1270. Epub 2011 Nov 17.


Redirected lysis of human melanoma cells by a MCSP/CD3-bispecific BiTE antibody that engages patient-derived T cells.

Torisu-Itakura H, Schoellhammer HF, Sim MS, Irie RF, Hausmann S, Raum T, Baeuerle PA, Morton DL.

J Immunother. 2011 Oct;34(8):597-605. doi: 10.1097/CJI.0b013e3182307fd8.


The interleukin-2 antagonizing antibody MT204 delays allogeneic skin graft rejection in non-human primates and is well tolerated.

Plater-Zyberk C, Lopes Estêvão DM, d'Argouges S, Haanstra KG, Kondova I, Vierboom M, Boehm T, Neef R, Vieser EM, Rattel B, Baeuerle PA, Jonker M.

Transpl Immunol. 2011 Sep;25(2-3):133-40. doi: 10.1016/j.trim.2011.06.003. Epub 2011 Jun 25.


Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

Topp MS, Kufer P, Gökbuget N, Goebeler M, Klinger M, Neumann S, Horst HA, Raff T, Viardot A, Schmid M, Stelljes M, Schaich M, Degenhard E, Köhne-Volland R, Brüggemann M, Ottmann O, Pfeifer H, Burmeister T, Nagorsen D, Schmidt M, Lutterbuese R, Reinhardt C, Baeuerle PA, Kneba M, Einsele H, Riethmüller G, Hoelzer D, Zugmaier G, Bargou RC.

J Clin Oncol. 2011 Jun 20;29(18):2493-8. doi: 10.1200/JCO.2010.32.7270. Epub 2011 May 16.


Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab.

Nagorsen D, Baeuerle PA.

Exp Cell Res. 2011 May 15;317(9):1255-60. doi: 10.1016/j.yexcr.2011.03.010. Epub 2011 Mar 16. Review.


Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies.

Münz M, Murr A, Kvesic M, Rau D, Mangold S, Pflanz S, Lumsden J, Volkland J, Fagerberg J, Riethmüller G, Rüttinger D, Kufer P, Baeuerle PA, Raum T.

Cancer Cell Int. 2010 Nov 2;10:44. doi: 10.1186/1475-2867-10-44.


Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cells.

Herrmann I, Baeuerle PA, Friedrich M, Murr A, Filusch S, Rüttinger D, Majdoub MW, Sharma S, Kufer P, Raum T, Münz M.

PLoS One. 2010 Oct 18;5(10):e13474. doi: 10.1371/journal.pone.0013474.


T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells.

Lutterbuese R, Raum T, Kischel R, Hoffmann P, Mangold S, Rattel B, Friedrich M, Thomas O, Lorenczewski G, Rau D, Schaller E, Herrmann I, Wolf A, Urbig T, Baeuerle PA, Kufer P.

Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12605-10. doi: 10.1073/pnas.1000976107. Epub 2010 Jun 28.


Phase II study of the human anti-epithelial cell adhesion molecule antibody adecatumumab in prostate cancer patients with increasing serum levels of prostate-specific antigen after radical prostatectomy.

Marschner N, Rüttinger D, Zugmaier G, Nemere G, Lehmann J, Obrist P, Baeuerle PA, Wolf A, Schmidt M, Abrahamsson PA, Reinhardt C, Heidenreich A.

Urol Int. 2010;85(4):386-95. doi: 10.1159/000318055. Epub 2010 Jul 2.


Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen.

Bluemel C, Hausmann S, Fluhr P, Sriskandarajah M, Stallcup WB, Baeuerle PA, Kufer P.

Cancer Immunol Immunother. 2010 Aug;59(8):1197-209. doi: 10.1007/s00262-010-0844-y. Epub 2010 Mar 23.


Human IgG1 antibodies antagonizing activating receptor NKG2D on natural killer cells.

Steigerwald J, Raum T, Pflanz S, Cierpka R, Mangold S, Rau D, Hoffmann P, Kvesic M, Zube C, Linnerbauer S, Lumsden J, Sriskandarajah M, Kufer P, Baeuerle PA, Volkland J.

MAbs. 2009 Mar-Apr;1(2):115-27. Epub 2009 Mar 11.


Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release.

Amann M, D'Argouges S, Lorenczewski G, Brischwein K, Kischel R, Lutterbuese R, Mangold S, Rau D, Volkland J, Pflanz S, Raum T, Münz M, Kufer P, Schlereth B, Baeuerle PA, Friedrich M.

J Immunother. 2009 Jun;32(5):452-64. doi: 10.1097/CJI.0b013e3181a1c097.


The emerging role of EpCAM in cancer and stem cell signaling.

Munz M, Baeuerle PA, Gires O.

Cancer Res. 2009 Jul 15;69(14):5627-9. doi: 10.1158/0008-5472.CAN-09-0654. Epub 2009 Jul 7. Review.


Bispecific T-cell engaging antibodies for cancer therapy.

Baeuerle PA, Reinhardt C.

Cancer Res. 2009 Jun 15;69(12):4941-4. doi: 10.1158/0008-5472.CAN-09-0547. Epub 2009 Jun 9. Review.


Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab.

Nagorsen D, Bargou R, Ruttinger D, Kufer P, Baeuerle PA, Zugmaier G.

Leuk Lymphoma. 2009 Jun;50(6):886-91. doi: 10.1080/10428190902943077. Review.


Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.

Lutterbuese R, Raum T, Kischel R, Lutterbuese P, Schlereth B, Schaller E, Mangold S, Rau D, Meier P, Kiener PA, Mulgrew K, Oberst MD, Hammond SA, Baeuerle PA, Kufer P.

J Immunother. 2009 May;32(4):341-52. doi: 10.1097/CJI.0b013e31819b7c70.


BiTE: Teaching antibodies to engage T-cells for cancer therapy.

Baeuerle PA, Kufer P, Bargou R.

Curr Opin Mol Ther. 2009 Feb;11(1):22-30. Review.


Mode of cytotoxic action of T cell-engaging BiTE antibody MT110.

Haas C, Krinner E, Brischwein K, Hoffmann P, Lutterbüse R, Schlereth B, Kufer P, Baeuerle PA.

Immunobiology. 2009;214(6):441-53. doi: 10.1016/j.imbio.2008.11.014. Epub 2009 Jan 20.


Nuclear signalling by tumour-associated antigen EpCAM.

Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M, Kieu C, Papior P, Baeuerle PA, Munz M, Gires O.

Nat Cell Biol. 2009 Feb;11(2):162-71. doi: 10.1038/ncb1824. Epub 2009 Jan 11.


On the abundance of EpCAM on cancer stem cells.

Gires O, Klein CA, Baeuerle PA.

Nat Rev Cancer. 2009 Feb;9(2):143; author reply 143. doi: 10.1038/nrc2499-c1. Epub 2009 Jan 9. No abstract available.


Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells.

d'Argouges S, Wissing S, Brandl C, Prang N, Lutterbuese R, Kozhich A, Suzich J, Locher M, Kiener P, Kufer P, Hofmeister R, Baeuerle PA, Bargou RC.

Leuk Res. 2009 Mar;33(3):465-73. doi: 10.1016/j.leukres.2008.08.025. Epub 2008 Oct 2.


Tumor regression in cancer patients by very low doses of a T cell-engaging antibody.

Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M, Einsele H, Brandl C, Wolf A, Kirchinger P, Klappers P, Schmidt M, Riethmüller G, Reinhardt C, Baeuerle PA, Kufer P.

Science. 2008 Aug 15;321(5891):974-7. doi: 10.1126/science.1158545.


Myocardial gene expression of matched hibernating and control tissue from patients with ischemic left ventricular dysfunction.

Zohlnhöfer D, Nührenberg TG, Haas F, Bengel F, Schömig A, Baeuerle PA, Schwaiger M.

Heart Vessels. 2008 Jul;23(4):230-42. doi: 10.1007/s00380-007-1035-4. Epub 2008 Jul 23.


Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans.

Amann M, Friedrich M, Lutterbuese P, Vieser E, Lorenczewski G, Petersen L, Brischwein K, Kufer P, Kischel R, Baeuerle PA, Schlereth B.

Cancer Immunol Immunother. 2009 Jan;58(1):95-109. doi: 10.1007/s00262-008-0529-y. Epub 2008 Jul 2.


Combined blockade of granulocyte-macrophage colony stimulating factor and interleukin 17 pathways potently suppresses chronic destructive arthritis in a tumour necrosis factor alpha-independent mouse model.

Plater-Zyberk C, Joosten LA, Helsen MM, Koenders MI, Baeuerle PA, van den Berg WB.

Ann Rheum Dis. 2009 May;68(5):721-8. doi: 10.1136/ard.2007.085431. Epub 2008 May 21.


Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3.

Amann M, Brischwein K, Lutterbuese P, Parr L, Petersen L, Lorenczewski G, Krinner E, Bruckmeier S, Lippold S, Kischel R, Lutterbuese R, Kufer P, Baeuerle PA, Schlereth B.

Cancer Res. 2008 Jan 1;68(1):143-51. doi: 10.1158/0008-5472.CAN-07-2182.

Supplemental Content

Loading ...
Support Center